European Pharmaceutical Review brings you the latest updates from regulatory bodies across the globe in response to the COVID-19 coronavirus.
COVID-19 and the UK
Health and Social Care Secretary Matt Hancock has set out emergency measures to give ministers powers to take the action to respond “effectively” to the progression of the COVID-19 coronavirus outbreak. The bill was introduced to Parliament last week.
According to the government, the measures in the coronavirus bill are temporary and reflect the level of threat posed by the virus.
The actions are intended to defend public health and ensure that National Health System (NHS) and social care staff have the required support to deal with significant extra pressure on the UK’s infrastructure.
This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.
Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.
What you’ll discover:
Key trends shaping the pharmaceutical formulation sector
Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
Falling into five categories, the measures include:
containing and slowing the virus
easing legislative and regulatory requirements
enhancing capacity and the flexible deployment of staff across essential services
managing the deceased in a dignified way
supporting and protecting the public to do the right thing and follow public health advice.
The powers enabled by the bill will allow recently retired NHS staff and social workers to return to work without any negative repercussions to their pensions.
NHS staff will also be covered by a state-backed insurance scheme to ensure they can care for patients if, for example, they are moving outside their day-to-day duties while making use of their skills and training.
Paperwork and administrative requirements will be reduced to help doctors discharge patients more quickly when clinically appropriate, to free up hospital space for those who are very ill and enable clinicians to focus on delivering care.
The bill allows the four UK governments to switch on these new powers when they are needed and to switch them off once they are no longer necessary.
The government highlights that the bill builds on the Treasury’s recent investment of £12 billion to support public services, people and businesses through the disruption caused by COVID-19 in the 2020 Budget.
Hancock said: “We are doing everything we can to protect lives and support the NHS, guided by the best scientists and clinicians in the world. The new measures we will be introducing in the Emergency Coronavirus Bill will only be used when it is absolutely necessary and must be timed to maximise their effectiveness, but crucially they give the government the powers it needs to protect lives. By planning for the worst and working for the best we will get through this, but this is a national effort and we must all work together ‒ from businesses prioritising the welfare of their employees, to people thoroughly washing their hands.”
US response to the coronavirus
In the US, President Donald Trump made a statement to press, after a meeting with the White House Coronavirus Task Force. He said that due to the “unprecedented” efforts and collaboration from the Food and Drug Administration (FDA), National Institutes of Health (NIH) and private companies, the first human clinical trial of a coronavirus vaccine has begun.
Trump also announced that the US would be taking further steps to expand testing capacity. He explained that a self-swab for testing individuals for COVID-19 is now in development, which would make diagnosis much easier.
In regard to the FDA, Trump commented that he would “cut through red tape” to reduce regulatory barriers.
The FDA itself announced that it has temporarily postponed all domestic routine surveillance facility inspections to maintain the health of its staff. According to the agency, all domestic for-cause inspection assignments will be evaluated and will proceed if mission-critical. The FDA says it will also continue to respond to natural disasters, outbreaks and other public health emergencies involving FDA-regulated products.
The regulatory body also announced an update to its policy on diagnostic testing for COVID-19.
It is putting a policy in place for states to take responsibility for tests developed and used by laboratories. States can set up a system in which they take responsibility for authorising these tests – the laboratories will not engage with the FDA. Instead, labs will engage directly with the appropriate state authorities.
The FDA is also expanding their previous guidance – under the update, the agency does not intend to object to commercial manufacturers distributing and labs using new commercially developed tests prior to the FDA granting an Emergency Use Authorisation (EUA), under certain circumstances.
The European Commission (EC) COVID-19 panel
All governments have to take well-informed and appropriate decisions”
Meanwhile in Europe, the EC has launched an advisory panel to discuss the impact of COVID-19 and consider management measures composed of seven members from six member states.
The group of epidemiologists and virologists will formulate EU guidelines on science-based and co-ordinated risk management measures.
EC President Ursula von der Leyen, who will chair the panel, said: “The coronavirus is rapidly changing our lives and societies. All governments have to take well-informed and appropriate decisions for the people of Europe every day. That is why scientific expertise and good advice is now more valuable than ever. I am very grateful to all the high-profile experts on the panel for putting their knowledge at the service of the community.”
The panel will provide advice to the EC on:
Formulation of response measures to be addressed to all member states in line with the different stages of the virus in the EU as a whole, taking into account particular contexts
Identification and mitigation of significant gaps, inconsistencies or inadequacies in measures taken or to be taken to contain and manage the spread of COVID-19, including in clinical management and treatment to overcome its impact
Prioritisation of healthcare, civil protection and other resources as well as support measures to be organised or co-ordinated at EU level
Recommendation of policy measures for addressing and mitigating long-term consequences of COVID-19.
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.